ARTES Announces a Strategic Collaboration Deal for Vaccine Development
Complete the form below to unlock access to ALL audio articles.
ARTES Biotechnology, specialized in recombinant protein production and process development in microbial expression systems, started a development collaboration for two vaccines together with global biopharmaceutical company Crucell.
Crucell is focused on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide.
Aim of the long-term research cooperation is a new-product development on the basis of ARTES’ virus like particle (VLP) and the well-established Hansenula polymorpha expression system fitting to Crucell’s vaccine portfolio.
The Hansenula system is the preferred technology for affordable mass vaccination and is recommended by the WHO for hepatitis B vaccination campaigns.
In combination, the unique yeast based VLP approach builds a new and very economical approach to low-cost mass production of safe and effective vaccines.
Under the terms of the long-term research collaboration ARTES is responsible for delivery of the production cell lines and processes to Crucell.
